NLS Pharmaceutics (NLSP) adds AEX-6xx CNS series developed by Aexon Labs

Rhea-AI Filing Summary

NLS Pharmaceutics Ltd. filed a report noting that it issued a new press release about expanding its central nervous system (CNS) drug pipeline. The press release, titled “NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs,” highlights a new series of CNS-focused compounds originating from Aexon Labs.

This step signals that NLS Pharmaceutics is adding additional product candidates to its research portfolio, potentially broadening its future development opportunities in neurological or psychiatric conditions, although no clinical, financial, or deal terms are described in this report.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of October 2025 (Report No. 8)

Commission File Number: 001-39957

NLS PHARMACEUTICS LTD.

(Translation of registrant’s name into English)

The Circle 6

8058 Zurich, Switzerland

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F       ☐ Form 40-F

CONTENTS

On October 30, 2025, NLS Pharmaceutics Ltd. issued a press release titled: “NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs.” A copy of this press release is furnished herewith as Exhibit 99.1.

EXHIBIT INDEX

Exhibit Number		Description of Document
99.1		Press release titled: “NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs”

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NLS Pharmaceutics Ltd.
Date: October 30, 2025	By:	/s/ Alexander C. Zwyer
		Name:	Alexander C. Zwyer
		Title:	Chief Executive Officer

2

FAQ

What did NLS Pharmaceutics (NLSP) disclose in its latest 6-K filing?

NLS Pharmaceutics disclosed that it issued a press release announcing expansion of its CNS pipeline with the AEX-6xx series developed by Aexon Labs. The filing mainly serves to furnish this press release as an exhibit for investors and regulators.

What is the main focus of the new NLS Pharmaceutics (NLSP) press release?

The main focus is that NLS Pharmaceutics is expanding its central nervous system pipeline with a new AEX-6xx series developed by Aexon Labs. This suggests additional CNS research assets entering the company’s portfolio, though detailed scientific or commercial terms are not included here.

Who is NLS Pharmaceutics partnering with for the AEX-6xx CNS series?

NLS Pharmaceutics is working with Aexon Labs, which developed the AEX-6xx series mentioned in the press release. The filing only states this development link and does not describe the structure of any partnership, licensing, or financial arrangements between the companies.

Does the NLS Pharmaceutics (NLSP) 6-K include financial or clinical data?

The 6-K does not include financial results or clinical trial data. It simply notes that a press release about expanding the CNS pipeline with the AEX-6xx series from Aexon Labs has been furnished as Exhibit 99.1, without additional quantitative disclosures.

When did NLS Pharmaceutics issue the press release about the AEX-6xx series?

NLS Pharmaceutics issued the press release on October 30, 2025. The same date appears on the 6-K, which formally furnishes the press release as an exhibit, documenting the company’s announcement about expanding its CNS development pipeline.